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Abstract
Eighty-six newly diagnosed multiple myeloma (MM) patients from a public hospital of São Paulo (Brazil) were evaluated by cIg-
FISH for the presence of del(13)(q14), t(4;14)(p16.3;q32) and del(17)(p13). These abnormalities were observed in 46.5, 9.3, 
and 7.0% of the patients, respectively. In order to identify the possible role of del(13)(q14) in the physiopathology of MM, we 
investigated the association between this abnormality and the proliferative and apoptotic indexes of plasma cells. When cases 
demonstrating t(4;14)(p16.3;q32) and del(17)(p13) were excluded from the analysis, we observed a trend towards a positive 
correlation between the proportion of cells carrying del(13)(q14) and plasma cell proliferation, determined by Ki-67 expression 
(r = 0.23, P = 0.06). On the other hand, no correlation between the proportion of cells carrying del(13)(q14) and apoptosis, 
determined by annexin-V staining, was detected (r = 0.05, P = 0.69). In general, patients carrying del(13)(q14) did not have 
lower survival than patients without del(13)(q14) (P = 0.15), but patients with more than 80% of cells carrying del(13)(q14) 
showed a lower overall survival (P = 0.033). These results suggest that, when del(13)(q14) is observed in a high proportion 
of malignant cells, it may have a role in determining MM prognosis. Another finding was a statistically significant lower overall 
survival of patients with t(4;14)(p16.3;q32) (P = 0.026). In the present study, almost half the patients with t(4;14)(p16.3;q32) died 
just after diagnosis, before starting treatment. This fact suggests that, in São Paulo, there may be even more patients with this 
chromosomal abnormality, but they probably die before being diagnosed due to unfavorable socioeconomic conditions. This 
could explain the low prevalence of this chromosomal abnormality observed in the present study.
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Despite recent progress in the management of multiple 
myeloma (MM), this neoplasm remains incurable and is charac-
terized by a heterogeneous prognosis. The variable prognosis 
of the disease involves interaction between intrinsic features of 
the disease biology such as chromosomal abnormalities and 
host factors. Del(13)(q14) is detected in almost 50% of cases 
and is associated with lower survival only when other high-risk 
genetic features such as del(17)(p13) and t(4;14)(p16.3;q32) 
are present (1,2). However, this does not mean that del(13)
(q14) has no biological importance since data suggest that this 
abnormality is a prerequisite for clonal expansion (1,2). 
The aim of the present study was to determine the preva-
lence of the most relevant chromosomal abnormalities and 
their impact on prognosis in a group of MM patients from a 
public hospital in São Paulo. Although these abnormalities 
have been studied extensively, there are few studies focus-
ing on their prevalence in developing countries (3-5). We also 
investigated the association between del(13)(q14) and the 
proliferative and apoptotic indexes of bone marrow plasma 
cells (PC) in order to study the possible role of this abnormality 
in the biology of the disease.
Patients and Methods
Patients
Bone marrow aspirates from 92 recently diagnosed 
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MM patients were obtained with a heparin-coated syringe. 
All patients were treated at Divisão de Hematologia, Hos-
pital das Clínicas, Universidade de São Paulo, and were 
diagnosed consecutively between February 2007 and April 
2011. The Institutional Ethics Review Board approved the 
study (protocol No. 016/06) and written informed consent 
was obtained from all patients allowing the specimen to be 
used for research purposes.
Patients received conventional dose induction chemo-
therapy consisting of a melphalan- or dexamethasone-
based ± thalidomide regimen (6). Fourteen patients received 
high-dose chemotherapy followed by autologous peripheral 
blood stem-cell support (ASCT) (6). The median follow-up 
was 37.3 months (0-54.8 months).
Fluorescence in situ hybridization (FISH) studies
Cytospin slides were prepared after enrichment of 
mononuclear cells, fixed in 95% ethanol for 5 min at room 
temperature and stored at -20°C for future use. We used 
cIg-FISH with light chain-specific immunofluorescent 
detection of clonal PC (7). Del(13)(q14) was determined 
with a retinoblastoma gene-1 LSI RB1 probe (Vysis, USA), 
del(17)(p13) with an LSI p53 probe (Vysis) combined with 
a chromosome 17 centromeric probe (Vysis), and t(4;14)
(p16.3;q32) with an LSI IGH/FGFR3 probe (Vysis). Two 
independent observers read blindly and independently each 
slide, counting a total of 200 nuclei per sample. The cut-off 
values (fusion probe = 10%, numerical abnormalities = 20%) 
adopted were in accordance with the recommendations of 
the European Myeloma Network FISH workshop (8).
Flow cytometry
Monoclonal antibodies (MoAb) anti-CD138-PE (DAKO, 
Denmark), anti-CD38-APC (eBioscience, USA) and anti-
CD45-PC5 (Immunotech-Beckman Coulter, France) were 
used to identify bone marrow PC. To detect proliferative 
cells, membrane cells were permeabilized with saponin and 
cells were stained with the anti-Ki-67 MoAb (Ki-67 FITC, 
Pharmingen, USA) (9). The Annexin-V-FITC kit (DAKO, 
The Netherlands) was used to detect phosphatidylserine 
expression on the surface of apoptotic cells after enrich-
ment of mononuclear cells using the Ficoll-gradient cen-
trifugation method. All acquisitions were performed using 
a FACSCalibur flow cytometer (BD Biosciences, USA) and 
the CellQuest program (BD Biosciences) and at least 2 x 
103 PC/tube were recorded.
Statistical analysis
Differences among groups were determined using the 
Fisher exact test for categorical variables. Differences 
among groups were determined using the Kruskal-Wallis 
test for continuous variables. Correlations between continu-
ous variables were investigated using the nonparametric 
Spearman test. 
Overall survival (OS) was calculated from the time of 
diagnosis to death from any cause or last contact using 
the Kaplan-Meier method. Event-free survival (EFS) was 
calculated from the time of diagnosis to progression, loss of 
response or death from any cause, or last contact, using the 
Kaplan-Meier method. The survival curves were compared 
by the log-rank test. All P values were 2-tailed and the alpha 
error was defined as 5%. The statistical analyses were 
performed using the Stata Statistical Software, Release 
11 (StataCorp LP, USA). 
Results
Characteristics of patients at diagnosis
The median age of the 92 patients was 63.5 years 
(range = 36-93); 51.2% were males. 
Sixty-four percent of patients had an IgG paraprotein, 
20.2% had an IgA paraprotein, 12.3% had light chains 
only (kappa = 5.6% and lambda = 6.7%), and 3.4% were 
non-secretory. Fifty percent of patients were classified as 
International Staging System (ISS) (10) stage III, 36.6% as 
stage II, and 13.4% as stage I. The clinical and laboratory 
features of the patients are summarized in Table 1.
Prevalence of chromosomal abnormalities 
The chromosomal abnormalities t(4;14)(p16.3;q32), 
del(17)(p13) and del(13)(q14) were studied in 86 patients 
and were detected in 8 (9.3%), 6 (7%), and 40 (46.5%) of 
them, respectively. There were no significant differences 
in age or gender between the different groups. The me-
dian age of patients with t(4;14)(p16.3;q32), del(17)(p13), 
and with only del(13)(q14) was 59 (range = 54-73), 57.5 
(range = 43-76), and 65 (range = 36-79), respectively. 
Forty patients with a median age of 63.5 years (range = 
36-93) did not have any of the abnormalities evaluated 
in this study. In 6 of 92 patients, it was not possible to 
study the different chromosomal abnormalities due to 
hybridization failure.
In del(13)(q14)-positive cases, the median number 
of PC with this abnormality was 75% (range = 28-98%). 
In t(4;14)(p16.3;q32)-positive cases, the median number 
of PC with this abnormality was 84% (range = 76-94%), 
and 6 of these patients also had del(13)(q14). In del(17)
(p13)-positive cases, the median number of PC with this 
abnormality was 35% (range = 21-76%) and 2 of these 
patients also had del(13)(q14). 
The majority of patients (84.8%) were treated just 
with conventional doses of chemotherapy. Only 14 pa-
tients received ASCT: 8 of them with at least one of the 
abnormalities studied, and 6 of them without any of these 
chromosomal alterations. The characteristics of patients 
according to their chromosomal abnormalities are de-
scribed in Table 1.
Del(13)(q14) versus PC proliferation and apoptosis 
Ki-67 MoAb staining was performed in 78 patients. The 
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percentage of Ki-67-positive PC ranged from 0 to 26% (me-
dian: 3.2%). Annexin-V staining was carried out in 69 cases 
and the percentage of annexin-V-positive PC ranged from 
0 to 55% (median: 8.1%). The percentage of Ki-67 expres-
sion and annexin-V labeling in PC according to clinical and 
laboratory characteristics is described in Table 2.
When the correlation between the percentage of PC 
carrying del(13)(q14) and proliferation was calculated, a 
weak correlation was found between Ki-67 expression and 
the proportion of cells carrying del(13)(q14) (r = 0.22, P = 
0.058). This finding persisted even when all cases with ad-
ditional t(4;14)(p16.3;q32) and del(17)(p13) were excluded 
in order to examine only the effect of del(13)(q14) on Ki-67 
expression (r = 0.23, P = 0.06). 
A cut-off of 8% was used for Ki-67 expression (11,12). 
Based on the ROC curve, we determined that the best 
threshold for the percentage of PC with del(13)(q14) that 
was associated with Ki-67 above 8% was greater than 75%. 
Indeed, whereas 54.5% of the cases with del(13)(q14) in 
at least 80% of their PC showed Ki-67 expression above 
8%, only 4% of patients carrying del(13)(q14) in less than 
80% of their PC showed Ki-67 expression above 8% (P 
< 0.001).
No correlation was detected between del(13)(q14) and 
annexin-V staining (r = 0.05, P = 0.69).
Due to the small number of cases positive for t(4;14)
(p16.3;q32) (N = 8) or del(17)(p13) (N = 6) in our sample, 
no attempt was made to establish a correlation between 
proliferative and apoptotic indexes and the proportion of 
cells with these abnormalities.
Survival analysis
The overall survival from diagnosis was analyzed, and 
a statistically significant difference was observed between 
patients with t(4;14)(p16.3;q32) and all other patients 
(estimated 3-year OS of 25 vs 62.2%, respectively, P = 
Table 1. Characteristics of patients according to chromosomal abnormalities.
All patients 
(N = 92)
Normal [normal 13q14 
and 17p13, and absence 
of t(4;14)] (N = 40)
del(13)(q14) [normal 
17p13 and absence of 
t(4;14)] (N = 32)
t(4;14) 
(N = 8)
del(17)(p13) 
(N = 6)
Age (years)
Median (range) 63.5 (36-93) 63.5 (36-93) 65 (36-79) 59 (54-73) 57.5 (43-76)
ISS
I/II 50% 57.1% 46.4% 28.6% 66.7%
III 50% 42.9% 53.6% 71.4% 33.3%
Hemoglobin
Median (range), g/dL 9.0 (4.4-16.1) 9.2 (5.6-13.4) 8.35 (4.4-16.1) 7.8 (6.8-12.7) 11.2 (9.1-13.0)
<10.0 g/dL 64% 60% 68.8% 87.5% 33.3%
Creatinine
Median (range), mg/dL 1.2 (0.38-15.6) 1.2 (0.56-12.2) 1.3 (0.38-15.6) 1.6 (0.81-5.2) 1.2 (0.7-2.4)
≥2.0 mg/dL 29.1% 25% 34.4% 37.5% 16.7%
Calcium
Median (range), mg/dL 9.9 (7.7-15.6) 9.9 (7.7-15.1) 10.0 (8.7-13.5) 12.2 (8.9-15.6) 9.5 (8.8-11.3)
≥10.5 mg/dL 41.6% 38.9% 42.9% 62.5% 20%
Albumin
Median (range), mg/dL 3.6 (1.7-5.1) 3.7 (2.3-4.6) 3.5 (1.7-4.8) 3.4 (2.6-3.8) 3.6 (3.2-5.1)
<3.5 g/dL 43% 32.5% 50% 62.5% 50%
β2-microglobulin
Median (range), µg/mL 5.5 (1.8-87) 4.9 (1.8-23) 6 (1.9-87) 10.5 (2.5-18.7) 4.3 (3-7.6)
≥3.5 µg/mL 79% 77.1% 82.1% 85.7% 66.7%
Lactate dehydrogenase
Median (range), U/L 338 (135-966) 320 (135-966) 346 (192-698) 408 (161-599) 313 (180-433)
Above normal (>480 U/L) 12.5% 7.7% 17.9% 28.6% 0%
Reactive C protein
Median (range), mg/L 10.9 (0.36-414) 12.2 (1.3-260) 10.6 (0.88-118) 36.3 (1.02-101) 3.9 (0.57-304)
Above normal (>3.0 mg/L) 74.2% 83.3% 66.7% 83.3% 50%
It was not possible to study the chromosomal abnormalities in 6 of 92 patients due to hybridization failure. ISS = International Staging 
System (10). There were no statistical differences among groups in continuous variables (P > 0.05, Kruskal-Wallis test).
Proliferation, apoptosis and chromosomal changes in myeloma 1077
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0.026). Del(17)(p13) was not associated with a lower 
estimated 3-year OS (P = 0.27). When cases with 
t(4;14)(p16.3;q32) and del(17)(p13) were excluded 
from the analysis, del(13)(q14) was also not associ-
ated with a lower estimated 3-year OS (P = 0.15; 
Figure 1A). 
As cases with at least 80% of cells affected by 
del(13)(q14) showed a higher proliferative index, 
we compared the OS between patients carrying this 
abnormality in more and in less than 80% of PC. We 
observed that patients with more than 80% of cells 
affected by del(13)(q14) had a shorter median OS 
than patients with less than 80% of cells affected 
by this abnormality (estimated 3-year OS of 27.8 vs 
67.6%, respectively, P = 0.015). When cases with 
t(4;14)(p16.3;q32) and del(17)(p13) were excluded 
from the analysis, this difference still remained 
(estimated 3-year OS 32.4 vs 69.1%, respectively, 
P = 0.033; Figure 1B). These patients were divided 
into three groups: group 1 [del(13)(q14) in less than 
80% of PC]; group 2 [del(13)(q14) in more than 80% 
of PC and Ki-67 expression below 8%], and group 
3 [del(13)(q14) in more than 80% of PC and Ki-67 
above 8%]. Only group 3 was associated with lower 
OS (estimated 3-year OS: group 1 = 66.2%, group 
2 = 50%, and group 3 = 0%, P = 0.01). 
The estimated 3-year EFS from diagnosis was 
similar in cases with t(4;14)(p16.3;q32), del(17)
(p13), del(13)(q14), and none of the abnormalities 
studied (P = 0.32). Although del(13)(q14) in more 
than 80% PC was also not associated with lower 
EFS (P = 0.72), the expression of Ki-67 above 8% 
was associated with it (P = 0.015). 
Figure 1. A, Overall survival (OS) in patients without del(13)(q14) (N = 40) and with del(13)(q14) (N = 32) and not t(4;14)(p16.3;q32) 
nor del(17p13) (P = 0.15, log-rank test). B, OS in patients harboring del(13)(q14) in less (N = 58) and in more (N = 14) than 80% of 
their plasma cells and not t(4;14)(p16.3;q32) or del(17)(p13) (P = 0.033, log-rank test).
Table 2. Association between characteristics of patients and Ki-67 ex-
pression and annexin-V labeling.
Ki-67 Annexin-V 
ISS
I/II 2.7% (0-26.4%) 8.3% (0.31-35.8%)
III 3.2% (0-24.7%) 7.3% (0.12-55.0%)
Hemoglobin
≥10.0 g/dL 2.5% (0.4%-20.9%) 6.7% (0.1-35.8%)
<10.0 g/dL 3.6% (0-26.4%) 9.5% (0.2-55.0%)
Creatinine
<2.0 mg/dL 3.2% (0-26.4%) 8.1% (0.1-55.0%)
≥2.0 mg/dL 3.1% (0-18.9%) 8.7% (0.7-49.5%)
Calcium
<10.5 mg/dL 3.1% (0-20.9%) 9.8% (0.1-49.5%)
≥10.5 mg/dL 3.6% (0.4-26.4%) 6.7% (0.7-27.7%)
Albumin
≥3.5 g/dL 2.7% (0-26.4%) 10.0% (0.1-55.0%)
<3.5 g/dL 3.7% (0-24.7%) 5.8% (0.2-49.5%)
β2-microglobulin
<3.5 µg/mL 2.2% (0.8-26.4%) 13.1% (0.8-35.8%)
≥3.5 µg/mL 3.2% (0-24.7%) 7.6% (0.1-55.0%)
Lactate dehydrogenase
≤480 U/L 2.8% (0-24.7%) 7.6% (0.1-55.0%)
>480 U/L 5.0% (0.4-26.4%)* 21.5% (0.3-29.4%)
Reactive C protein
≤3.0 mg/L 2.3% (0-6.5%) 8% (1-32.1%)
>3.0 mg/L 4.6% (0-26.4%)* 6.4% (0.1-55.0%)
Data are reported as median with range in parentheses. ISS = International 
Staging System (10). *P < 0.05, Ki-67 expression of above normal data com-
pared to normal data (Kruskal-Wallis test).
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Discussion
The prevalence of del(13)(q14) and del(17)(p13) was 
similar to that observed in studies carried out in other 
countries. However, t(4;14)(p16.3;q32) was observed in a 
lower percentage of patients than in other studies (1). In 
the present study, t(4;14)(p16.3;q32) was associated with 
a very dismal prognosis, with almost half the patients dying 
immediately after diagnosis, before starting treatment. This 
suggests that, in São Paulo and perhaps in Brazil, there may 
be even more patients with this chromosomal abnormality, 
but they may die before being diagnosed due to unfavorable 
socioeconomic conditions, leading to under-detection of this 
chromosomal abnormality in our population. 
We also observed that del(13)(q14) was associated 
with a poorer outcome when present in more than 80% of 
myeloma cells. Only 15.4 and 18.9% of patients with del(13)
(q14) in more than and in less than 80% of PC, respectively, 
received ASCT (data not shown). Therefore, we could not 
detect any significant difference in therapy administered to 
the two groups that would justify this difference. 
Our results suggest that, in the group of patients evalu-
ated in this study, the proportion of cells with del(13)(q14) 
was more important for determining prognosis than the 
raw presence of this abnormality in myeloma cells. Since 
the late nineties, the presence of del(13)(q14) in myeloma 
cells has been associated with a poor prognosis (13,14), 
although Avet-Loiseau et al. (15) and Gutierrez et al. (16) 
showed that most of the prognostic power of this abnor-
mality was related to its frequent association with t(4;14)
(p16.3;q32) and del(17)(p13). Despite the limited value of 
del(13)(q14) as a sole abnormality in the determination of 
prognosis, we decided to evaluate its association with the 
proliferative and apoptotic indexes of plasma cells in order 
to unveil if this abnormality has any importance in the biol-
ogy of the disease.
While Gastinne et al. (11) did not detect an associa-
tion between del(13)(q14) and increased cell proliferation, 
Fonseca et al. (14) and Zojer et al. (13) reported a positive 
relationship between del(13)(q14) and higher growth fraction 
(determined by Ki-67 staining or S-phase). However, these 
studies did not report the status of other important cytoge-
netic abnormalities such as del(17)(p13), t(4;14)(p16.3;q32) 
or t(14;16)(q32;q23). A recent study showed an association 
of higher PC proliferative index with del(13)(q14) but not 
with other chromosomal abnormalities (17). 
Gastinne et al. (11) and Alexandrakis et al. (12) previ-
ously described a cut-off of 8% for Ki-67 expression for 
prognosis in MM. Our study showed that there is an asso-
ciation between del(13)(q14) in more than 80% of PC and 
a higher Ki-67 expression (>8%), and that this association 
persisted even when patients with t(4;14)(p16.3;q32) and 
del(17)(p13) were excluded from the analysis. Also, the 
lower OS in the group of patients with more than 80% of 
PC affected by del(13)(q14) was observed only in cases 
with high Ki-67 expression. Thus, probably the cause of this 
unfavorable prognosis is not merely the presence of del(13)
(q14) in PC, but also their higher proliferative index. 
One hypothesis is that del(13)(q14) may be involved in 
the allelic loss of a tumor suppressor gene. As suggested 
by Fonseca et al. (14), additional mechanisms could lead 
to inactivation of the second allele, resulting in a complete 
loss of normal function of the affected gene, selecting 
these cells to become more proliferative. Consequently, 
the cells with del(13)(q14) would preferentially accumulate. 
On the other hand, when the majority of PC are affected by 
del(13)(q14), but the cause is not a proliferative advantage 
of these cells, the prognosis is not unfavorable. As far as 
we know, correlation between del(13)(q14) and apoptosis 
has not been studied before and our results suggest that 
del(13)(q14) is not important for cell apoptosis control. Other 
genetic mechanisms may be more relevant for this biologic 
feature than 13q14 status.
Another finding of the present study was that patients 
with del(17)(p13) did not have an unfavorable prognosis. 
This may be due to the low number of patients studied or 
to the low proportion of cells with this abnormality in the 
affected patients (median = 35%, range = 21-76%). These 
findings strengthen those described by Avet-Loiseau et al. 
(15,18), who suggested that cases with more than 74% of 
plasma cells affected by del(13)(q14) or with more than 
60% of plasma cells affected by del(17)(p13) were charac-
terized by a worse outcome than patients harboring these 
abnormalities in a smaller proportion of cells. 
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